Teva develops, manufactures, and markets generic pharmaceuticals, selected branded treatments, and biopharmaceutical products worldwide. Its specialty portfolio includes treatments for neurological and immunological conditions, while its generics business supplies lower-cost versions of medicines across numerous therapeutic categories. The company also develops biosimilars and complex generic formulations.
Teva Pharmaceutical Industries Ltd. ADR (TEVA) has a MarketKingdoms composite score of 63.5 (B-), an B-range rating. It ranks 967th of 1,866 covered companies, 45th of 78 in Healthcare (sector average 64.4) and 3rd of 6 in Drug Manufacturers - Specialty & Generic. Scores as of 2026-10-26.
Its strongest lenses are Stock selection at 80 (Healthcare average 79) and Trend (momentum) at 79 (Healthcare average 50). Its weakest lenses are Quality (profitability) at 43 (sector average 50) and Expansion (growth) at 47 (sector average 50).
| Lens | Type | TEVA | Healthcare average | Drug Manufacturers - Specialty & Generic average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 74 | 81 | 74 | 15th |
| Stock selection | Research signal | 80 | 79 | 76 | 54th |
| KPI momentum | Research signal | 78 | 78 | 71 | 48th |
| Catalyst watch | Research signal | 75 | 74 | 71 | 56th |
| Price (valuation) | Fundamental lens | 53 | 50 | 65 | 54th |
| Expansion (growth) | Fundamental lens | 47 | 50 | 39 | 51st |
| Quality (profitability) | Fundamental lens | 43 | 50 | 63 | 42nd |
| Trend (momentum) | Fundamental lens | 79 | 50 | 48 | 91st |
The most recent call analysed was held on 2026-07-29 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -29.4%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 0.71, sector beta 0.67, industry beta -0.12; the factor model explains 16% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Ironwood Pharmaceuticals Inc. (IRWD) | 76.7 | A- | -66.6% |
| Viatris Inc. (VTRS) | 63.8 | B- | -13.1% |
| United Therapeutics Corp. (UTHR) | 62.7 | B- | -10.5% |
| Haleon plc ADR (HLN) | 60.7 | B- | +4.3% |
| Zoetis Inc. (ZTS) | 51.2 | C | -2.7% |
Teva Pharmaceutical Industries Ltd. ADR financial statements · Healthcare sector ranking · Drug Manufacturers - Specialty & Generic industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.